N/A N=40 CLARITI (TM) 1-Day Multifocal Contact Lenses Performance and Acceptance Evaluation
Presbyopia Correction
Primary: Distance LogMAR Visual Acuity — -0.466; -0.972; -2.842; -3.768 LogMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Heart Function in HIV-Negative Children Exposed to HIV and HAART
HIV Infections
Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27
N/A N=285 Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses
Vision Disorders
Primary: Overall Comfort — 63.07; 71.87 units on a scale
Phase 2 N=237 A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
Migraine · Headache
Primary: Mean Change From Baseline in Monthly Migraine Days — 8.2; 8.2; -1.7; -1.3 Days/month — p=0.33153
N/A N=24 Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear
Corneal Swelling
Primary: Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit — 0.07; -0.02; 0.14; -0.06 percentage of change from baseline
Phase 2 N=72 Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis · ALS
Primary: The Difference in the Changes of Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Between Treatment Groups and Control Groups. — -1.36; -4.67…
Phase 1 N=21 Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
Healthy Volunteers
Primary: Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban — 190.873; 181.862; 153.693 ng/mL
N/A N=27 Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer
Diabetic Foot Ulcer · Diabetic Foot
Primary: Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking — 0.758; 0.272 Absolute change in temperature degrees
Phase 2 N=62 Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)
Hirschsprung Disease
Primary: Number of Patients Diagnosed With Hirschsprung-associated Enterocolitis (HAEC). — 10; 7 participants — p==0.897
N/A N=536 XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Angina · Coronary Occlusion · Coronary Artery Disease
Primary: Number of Participants With Acute Stent Thrombosis (ST) — 0; 0; 0; 0 Participants
N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Phase 3 N=132 A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
Anemia
Primary: Percentage of Participants Who Maintained Their Mean Hemoglobin Concentration Within +/- 1.0 Gram/Deciliter of Their Reference Hemoglobin Concentration and Between 10.0…
N/A N=275 Study of Ultrasound Imaging to Predict Time and Outcome in Pregnancies With Induced Labor
Pregnancy · Labor, Induced
Primary: Vaginal Delivery in Induced Labors — 62; 61; 63; 60 percentage of area under the ROC curve
Phase 2 N=54 A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts
Plantar Warts
Primary: Lesion Assessment — 8.42; 9.14; 8.42; 8.71 millimeters — p=<0.001
N/A N=284 Stroke Swallowing Screening Tool Validation
Cerebrovascular Disorders · Deglutition Disorders
Primary: Sensitivity of Screening Items — 37.9; 3.5; 62.1; 10.3 percentage of agreement